Logo
Whalesbook
HomeStocksNewsPremiumAbout UsContact Us

Morepen Laboratories Ltd

₹ 43.41.76%
04 Dec – close price
🔗morepen.com•BSE: 500288•NSE: MOREPENLAB
Market Cap₹ 2,378 Cr.
Current Price₹ 43.4
High / Low₹ 91.7
Stock P/E42.3
Book Value₹ 21.8
Dividend Yield0.46 %
ROCE13.2 %
ROE9.81 %
Face Value₹ 2.00
Sales₹ 1,546 Cr.
OPM7.03 %
Mar Cap₹ 2,378 Cr.

ABOUT

Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.[1]

KEY POINTS

Market LeadershipThe company is a leader in the pharmaceutical and medical devices industry, holding the top position in 6 APIs with the following market shares as of H1 FY25:Montelukast (anti-asthmatic):70%Loratadine (anti-allergy):69%Desloratadine (anti-allergy):49%Fexofenadine (anti-allergy):31%Atorvastatin (cholesterol reducer): 20%Rosuvastatin (cholesterol reducer):19%Additionally, it is a leader in other products including Sitagliptin, Linagliptin, Dapagliflozin, etc.[1][2]

Also present in buckets:
Credit Rating UpdatesRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1818.3037.81436512.690.883124.952.5614478.318.9320.2154964.0130.1211543.963117.955.6112.970.07
2.Divi's Lab.6469.0069.11171747.590.46689.0035.102715.0016.1220.4410029.0032.372485.00689.0011.1413.530.01
3.Torrent Pharma.3795.7059.34128559.890.84591.0032.493302.0014.3027.0512248.0032.602166.53600.1715.2013.260.33
4.Cipla1521.0022.58122853.860.851353.373.737589.447.6422.7228349.5725.405441.141351.173.7314.720.01
5.Dr Reddy's Labs1277.6018.48106643.700.631336.807.288828.309.8322.6934310.0024.645772.201347.102.9612.950.16
6.Lupin2092.0022.0995531.680.571484.8373.347047.5124.2321.3024750.6927.254324.631477.924.8712.410.32
7.Zydus Lifesci.935.7518.7094062.771.181238.6040.926123.2016.9224.3124493.9031.105029.351283.603.7214.640.38
8.Morepen Labs.43.4542.312378.070.4614.38-57.59369.53-3.6913.191546.007.0356.2013.542.006.770.13
–Median: 148 Co.409.7731.911710.390.1212.5712.32152.6410.5414.76582.8715.9344.5513.493.188.390.22

Quarterly Results

Standalone figures in ₹ crores

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales
274.40383345337369381395393386384403382391370
Expenses
260.80356323321344352344336337341372352372342
Operating Profit
13.6027211525305156494332301928
Other Income
0.711132344355346
Profit before tax
9.5523181322274753474330171119
Tax %
28.06%28%28%21%27%27%25%24%26%26%25%31%29%24%
Net Profit
6.881713101620354035322312814
EPS in Rs
0.140.320.250.200.310.390.690.780.690.580.410.220.150.26

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
3363704525485617177921,1121,4491,3391,5381,5551,546
Expenses
2903243884875016527281,0001,3201,2621,3761,4011,437
Operating Profit
4647646060656411212977162153109
Other Income
41-3444912106131618
Interest
1091074222-724713
Depreciation
46393534333834282118222436
Profit before tax
-611623262937941266314913878
Net Profit
-611623262932941014611110257
EPS in Rs
-0.140.010.350.520.580.640.722.102.110.902.171.851.04
Dividend Payout %
0%0%0%0%0%0%0%0%0%0%0%11%–

Compounded Sales Growth

10 Years:15%
5 Years:14%
3 Years:2%
TTM:-1%

Compounded Profit Growth

10 Years:68%
5 Years:26%
3 Years:0%
TTM:-60%

Stock Price CAGR

10 Years:4%
5 Years:6%
3 Years:11%
1 Year:-50%

Return on Equity

10 Years:13%
5 Years:13%
3 Years:10%
Last Year:10%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
909090909090909096102102110110
Reserves
1151031191341611882173555036787871,0721,083
Borrowings
2092001861681341391421719252896158
Other Liabilities
95106139155206203212385417300362444359
Total Liabilities
5085005355485916196628481,0331,1061,2791,7211,710
Fixed Assets
289244216191182153135144156171217366442
Gross Block
902907914922890777642516479512477649–
Accumulated Depreciation
613663698731708625507372323341261283–
CWIP
-0-0-0-0-0-0-021417242826
Investments
118118118118118118119119118118126205138
Other Assets
1001382012392913494085837458009121,1221,104
Total Assets
5085005355485916196628481,0331,1061,2791,7211,710

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
3351504961151149-69-1027729
Cash from Investing Activity
-1-30-27-15-24-10-12-69-23-36-84-280
Cash from Financing Activity
-29-20-28-31-38-0547661440260
Net Cash Flow
31-53-14328-256-69

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
444865557262565156707569
Inventory Days
6056536879719384958585107
Days Payable
122124140126176123111958086103127
Cash Conversion Cycle
-18-21-22-3-2510384071695750
Working Capital Days
-17-18-6-91-66-35-91658105104122
ROCE %
0%2%8%8%8%8%9%21%22%9%18%13%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
38.22%38.22%38.22%38.22%38.22%38.22%38.22%35.66%35.66%35.66%35.66%35.66%
FIIs
0.89%0.96%1.00%1.29%2.11%1.85%1.67%2.08%2.22%1.94%1.72%1.62%
DIIs
3.74%2.93%2.32%2.27%2.21%2.15%2.14%1.69%1.64%1.67%1.50%1.49%
Public
57.15%57.88%58.45%58.20%57.46%57.76%57.96%60.57%60.46%60.72%61.09%61.22%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Morepen Labs Faces GST Show Cause Notice for ₹11.79 Cr Refund Claim (Dec 4, 2025)

4th December 2025, 12:34 PM

Morepen Labs Reports Physical Share Transfer Status for November 2025

1st December 2025, 4:58 PM

Morepen Laboratories Publishes Q2 FY26 Financial Results

15th November 2025, 8:47 AM

Morepen Laboratories Q2 FY26: CARE Ratings Confirms QIP Fund Utilization; Flags Profitability Concerns

14th November 2025, 3:45 PM

Morepen Laboratories Q2 FY26 Results: Consolidated PAT Up 17.3% Driven by Exceptional Gains, Standalone PAT Dips 55%

14th November 2025, 3:18 PM

Published by Other Websites

External media mentions & references

Morepen Labs gets show-cause notice from the tax authorities for Rs 177 crore GST refund

4th December 2025, 11:24 AM

Three-day pharma industry event from Nov 25 to host global pharma leaders, exhibitors, investors

15th November 2025, 6:22 AM

Indian Equity Market Ends Week Higher on GST Reforms, Fitch Upgrade and Global Cues

13th September 2025, 6:52 AM

Morepen Laboratories shares jump 6%; what's driving buying interest?

9th September 2025, 5:34 AM

Medicine bills could see a 6-7% dip, say healthcare representatives

4th September 2025, 8:39 AM

News Articles

Editorial & research coverage

Morepen Labs gets show-cause notice from the tax authorities for Rs 177 crore GST refund
Morepen Labs gets show-cause notice from the tax authorities for Rs 177 crore GST refund

4th December 2025, 11:24 AM

Three-day pharma industry event from Nov 25 to host global pharma leaders, exhibitors, investors
Three-day pharma industry event from Nov 25 to host global pharma leaders, exhibitors, investors

15th November 2025, 6:22 AM

Documents

Announcements

Disclosure Under Regulation 30 (LODR)

7h - SCN from Shimla GST alleging ₹117.94 crore erroneous refund claim for FY2020–21 to 2023–24. ,"checklist":["Review announcement text for key facts and dates","Identify regulatory authority, amounts, …

Report On Transfer Requests Of Physical Shares Re-Lodged Under The Special Window

1 Dec - No physical share transfer re-lodgement requests received or processed in November 2025 under SEBI special window.

Announcement under Regulation 30 (LODR)-Newspaper Publication

15 Nov - Newspaper Publication-Financial Results for the quarter and half year ended September 30, 2025

Announcement under Regulation 30 (LODR)-Monitoring Agency Report

14 Nov - CARE report on QIP Rs.200 crore to Sept 30, 2025; Rs.35.02 crore unutilised, no deviations.

Announcement under Regulation 30 (LODR)-Investor Presentation

14 Nov - Investor Presentation Q2 FY 26 Financial Results

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from bse)

Financial Year 2012

(from bse)

Financial Year 2011

(from bse)

Credit Ratings

Rating update

22 Aug from infomerics

Concalls

Nov 2025

PPT

Aug 2025

PPT

May 2025

TranscriptPPTRecording

Feb 2025

TranscriptPPT

Nov 2024

TranscriptPPT

Aug 2024

TranscriptPPTRecording

May 2024

TranscriptPPTRecording

May 2024

PPT

Feb 2024

TranscriptPPT

Nov 2023

TranscriptPPT

Aug 2023

PPT

May 2023

PPT

Feb 2023

PPT

Nov 2022

PPT

Jul 2022

PPT

May 2022

TranscriptPPT

Feb 2022

TranscriptPPT

Nov 2021

TranscriptPPT

Jul 2021

TranscriptPPT

May 2021

TranscriptPPT

Feb 2021

TranscriptPPT

Nov 2020

TranscriptPPT

Sep 2020

TranscriptPPT

Jul 2020

TranscriptPPT

Feb 2020

PPT

Nov 2019

PPT

Aug 2019

PPT

May 2019

TranscriptPPT

Feb 2019

PPT

Nov 2018

PPT

Aug 2018

PPT

Aug 2018

PPT

Jun 2018

Transcript

May 2018

PPT

Feb 2018

TranscriptPPT